Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Q3 FY2025 Earnings Presentation
20 slides from Piramal Pharma's earnings presentation, January 2025
Slide 1: Q3 & 9M FY2025 Results
Q3 & 9M FY2025 Results January 2025
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner,
Slide 3: Key Performance Highlights of Q3FY25 / 9MFY25
Key Performance Highlights of Q3FY25 / 9MFY25 Revenue from Operation 9MFY25 Revenue Break-up (In ₹ Crore) 13% 14% 13% 2,204 6,397 1,959 5,619 30% 57% Q3FY24 Q3FY25 9MFY24 9MFY25 EBITDA and EBITDA Margins (In ₹ Crore) 850 100 % 120 0 100 % EBITDA 17% 16% 15% 15% 90% 90% 750 110 0 Margin 650 80% 80% 1
Slide 4: Key Performance Highlights of Q3FY25 / 9MFY25 - Segments
Key Performance Highlights of Q3FY25 / 9MFY25 Key Highlights Revenue (In ₹ Cr) and Growth 13% 18% • Continued momentum in revenue from on-patent commercial manufacturing 3,659 CDMO • YoY improvement in EBITDA margin driven by operating leverage and cost optimization 3,101 1,134 1,278 • Converted coa
Slide 5: Business Wise Performance
Business Wise Performance
Slide 6: CDMO Business
CDMO Business Performance Highlights Revenue Growth (In ₹ Crore) ❖ Robust high-teen revenue growth in 9MFY25 driven by: • Continued momentum in on-patent commercial manufacturing 13% 18% • Healthy demand in generic API business 3,659 • Timely capacity expansions and targeted BD1 efforts driving incr
Slide 7: Maintaining our Best-in-Class Quality Track Record
Maintaining our Best-in-Class Quality Track Record 360+ Regulatory Inspections with no OAI ~130 Audits Annually by Customers US FDA Inspections Total Regulatory Inspections 44 36 36 197 35 167 163 172 29 29 157 148 26 27 140 141 142 25 24 116 115 17 42 99 14 32 32 13 26 35 71 10 21 20 24 29 60 10 23
Slide 8: A Significant Step Towards Sustainable Operations
A Significant Step Towards Sustainable Operations Converted the coal-fired steam boiler at our Digwal facility to operate on biomass briquettes, a carbon-neutral fuel source • Will eliminate ~24,000 tCO2e GHG emissions annually, accounting for ~17% of total emissions • The shift to biomass briquette
Slide 9: Complex Hospital Generics Business
Complex Hospital Generics Business Performance Highlights Revenue Growth (In ₹ Crore) ❖ Inhalation Anesthesia • IA sales in the US tracking healthy volume growth driven by order wins for 14% 8% Sevoflurane and Isoflurane • Maintain our #1 Rank in Sevoflurane in the US with over 40%* market share • R
Slide 10: India Consumer Healthcare Business
India Consumer Healthcare Business Performance Highlights Revenue Growth (In ₹ Crore) ❖ New Product launches - 16 new products and 23 new SKUs launched in 9MFY25 10% 10% 819 747 ❖ Power Brands grew 19% YoY during 9MFY25, contributing 48% to total ICH sales • Excluding i-range (impacted by regulatory
Slide 11: Investing for Profitable Growth
Investing for Profitable Growth Continuous Media and Trade Spends… …Fueling Growth of Power Brands… (In ₹ Crore) (In ₹ Crore) % of ICH 16% 15% 15% 448 sales 396 45000% 200 13% 12% 16% 14% 370 40000% 35000% 131 131 12% 268 116 150 30000% 10% 84 98 8% 194 25000% 100 20000% 6% 15000% 4% 50 10000% 2% 50
Slide 12: Onboarded Sai Ramana Ponugoti – CEO, ICH Business
Onboarded Sai Ramana Ponugoti – CEO, ICH Business With over 20 years of leadership experience at Procter & Gamble (P&G), Mr. Sai Ramana Ponugoti has held senior roles across India, Asia, the Middle East, and Africa. As the Chief Sales Officer for P&G India, he has led transformative disruptions, dri
Slide 13: Financials
Financials
Slide 14: Consolidated Financials Highlights
Consolidated Financials Highlights (in ₹ Cr. or as stated) Particulars Q3FY25 Q3FY24 YoY Change 9MFY25 9MFY24 YoY Change Revenue from Operations* 2,204 1,959 13% 6,397 5,619 14% CDMO 1,278 1,134 13% 3,659 3,101 18% CHG 654 576 14% 1,928 1,782 8% ICH 278 252 10% 819 747 10% EBITDA 350 330 6% 977 815
Slide 15: Strategic Goals
Strategic Goals
Slide 16: Financial Aspirations for FY2030
Financial Aspirations for FY2030 3x 2x 1x Over 3x Growth in More than Double the Reduce Leverage EBITDA Revenues on the Balance Sheet ~25% US$2+ Bn ~1x EBITDA Margins Revenue Net debt to EBITDA Exponential Growth Enhance ROCE in PAT Early Teens PAT Margins High Teens ROCE Note:- The aspirations ment
Slide 17: US$2+ Bn Company with 25% EBITDA Margin by FY2030
US$2+ Bn Company with 25% EDITDA Margin by FY2030 Strategic Goals for FY2030 US$1.2 Bn revenues with ~25% US$600 Mn revenues with 25%+ US$200 Mn revenues with double-digit EBITDA margin EBITDA margin EBITDA margin CDMO CHG ICH Emerge as a fast-growing, innovation- Become a leading critical care comp
Slide 18: Key Investment Highlights
Key Investment Highlights US$2+ Bn Global Pharma, Health & Wellness Company by FY2030 1 Strong promoter group with over 35 years of demonstrated ability to build scalable and differentiated businesses 2 Presence in large multi-billion dollar size attractive industry segments with promising tailwinds
Slide 19: Dial-in details for Q3 and 9M FY25 Earnings Conference Call
Dial-in details for Q3 and 9M FY25 Earnings Conference Call Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) India – 05:30 PM IST 1 800 120 1221 (Toll free number) Conference USA – 07:00 AM Toll free number Call on 29th (Eastern Time – New York) 18667462133
Slide 20: For Investor Queries
For Investor Queries: Gagan Borana Madhusudan Dalmia Investor Relations and Enterprise Risk Management Investor Relations Email: gagan.borana@piramal.com Email: madhusudan.dalmia@piramal.com